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Abstract 
BACKGROUND: Neurofibromatosis is a genetic disease with an autosomal dominant type of inheritance. It is a 
multisystem disease in which, besides skin manifestations, there is a possibility for the involvement of other 
organs and systems, and an atypical variant of neurofibromatosis type 1 can also be observed- the so-called 
plexiform neurofibroma. In patients with this inherited disease, mortality is higher due to the existing risk for 
malignant transformation and development of malignant peripheral nerve sheath tumours (MPNSTs) or 
neurofibrosarcoma. 
CASE REPORT: We present a 25-year-old woman with neurofibromatosis type 1 and a family history of the 
disease-father and grandmother with NF-1, with fatal outcome in the grandmother as a result of malignant 
transformation to neurofibrosarcoma. The patient has clinical data for multiple cafés- au- lait spots on the skin of 
the trunk, upper and lower limbs, and plexiform tumour formation in the seating area. From the performed imaging 
diagnostic there are available MRT data for 1) giant pelvic neurofibroma, 2) plexiform giant neurofibroma in the 
subcutaneous fat on the right thigh and gluteal fat tissue to the right, passing through the midline in the area of the 
external genitalia, leading to deformation of the front wall of the sacrum with bilateral meningoceles and 3) diffuse 
involvement of the bladder wall from the process in the area of the trigonum vesicae felleae/the two urethral 
ostium, as well as 4) the presence of neurofibromas in the course of the iliac vessels on the right. Surgical 
removal of the oval pelvic formation, identified as neurofibroma was planned, as well as the initiation of systemic 
therapy with Sirolimus for the plexiform sciatic formation, infiltrating the bladder. 
CONCLUSION: Neurofibromatosis type-1 is a problematic disease due to the parallel systemic involvement of 
different organs and systems, which can be both limited and diffuse. Limited tumour lesions in the form of 
neurofibromas with diverse localisation (as in the patient we describe) could be surgically removed without 
difficulty. On the other hand, the diffuse involvement of internal organs within a giant, network-3spreading 
plexiform neurofibromas (as in the described patient) makes interdisciplinary interventions impossible, and 
therefore therapeutic alternatives should be considered. 
 
 
 
 
 
 
Introduction 
 
Neurofibromatosis was first described in 1882 
by Von Recklinghausen as a genetic neuroectodermal 
abnormality with systemic and progressive 
involvement, which mainly affected the skin, nervous 
system, bones, eyes and possibly other organs [1]. It 
is estimated that about one million people worldwide 
are living with NF [1]. Neurofibromatosis type 1 is a 
multisystem autosomal dominant disease, with 
cutaneous manifestations such as café-au-lait spots, 
multiple neurofibromas, ephelides in the skin fold 
areas, and hamartomatous lesions in the eyes, bones, 
glands and the central nervous system [1], [2]. 
Uncommon variants of NF-1 are the so-called 
plexiform neurofibromas in which neurofibromas arise 
from multiple nerves that may also engage connective 
tissue and skin folds and are clinically described as 
"bags of worms" [3]. Patients with neurofibromatosis 
are at risk for malignant transformation, as on the one 
hand having an increased risk of developing 
malignant peripheral nerve sheath tumours 
(MPNSTs), and on the other are threatened by a 
transformation to neurofibrosarcoma, which should be 
suspected if the initial lesion grows rapidly and 
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significantly [4], [5], [6]. We describe a patient with 
neurofibromatosis type 1, miction disorders and giant 
pelvic neurofibroma. 
 
 
Case Report 
 
We present a 25-year-old woman with a 
family history for neurofibromatosis type 1. According 
to anamnestic data, father and grandmother suffer 
from neurofibromatosis type 1, as in the grandmother 
being observed lethal outcome as a result of the 
transition from plexiform neurofibroma to 
neurofibrosarcoma in the neck area. The first 
symptoms date back to the age of 2-3 when multiple 
café-au- lait spots were observed all over the body 
and appearance of tumour formation in the neck and 
genital area (Figures 1a-1d). At the age of 3 
labiaplasties were performed on the pubic lips. By 
entering puberty, tumour formations in the neck area 
and genitals begin to increase in size. In 2015, the 
patient was hospitalised in a plastic-restorative and 
aesthetic surgery department, where step by step the 
skin and some parts of the plexiform neurofibromas in 
the lumbosacral, the sciatic, genital, and upper-medial 
area of the right thigh have been removed. 
 
Figure 1: A), B) Clinical examination: in the area of the genitals, the 
gluteal region and the upper medial part of the right hip, a plexiform 
tumour-like formation with a darker-skin-colour appearance, which 
resembles clinically as "worm bag" (Figures 1a and 1b) was 
observed; C), D): Clinical view of numerous café-au-lait spots on 
the skin of the upper limbs 
In 2016, due to recurrent bladder infections, 
the patient was directed to a urology department 
where small pelvis MRI was performed. The results 
showed an enlarged, hypotonic bladder with multiple 
diverticula (Figures 2b, 2d). In addition to the right of 
the bladder and ovary, an 82/50/50 mm formation with 
sharp and smooth outlines was visualised (Figures 
2a-2c). The formation has a characteristic of giant 
pelvic neurofibroma (Figures 2a-2c). 
 
Figure 2: A), B), and C) An MRI images of abdomen, small pelvis, 
gluteal area and thighs with data for a 9cm mass with irregular 
shape, lying on the right side of the pelvis and a conclusion about 
giant pelvic neurofibroma; D) MRI of a small pelvis showing an 
enlarged, hypotonic bladder with multiple diverticulitis 
 
Within the dermatological examination, a 
tumour formation was observed in the genital, buttock 
area and upper-medial part of the right thigh with 
darker skin colour, resembling clinically as a "worm 
bag"-plexiform neurofibroma in the sciatic area 
(Figures 1a-1b). Also, the presence of multiple cafés- 
au- lait on the skin of the trunk, upper and lower 
extremities were found (Figures 1c-1d). 
An additional MRI of a small pelvis with 
contrast revealed data for deformation of the sacrum 
on the front wall with bilateral meningoceles at Ec1 
and Ec2 levels (Figures 3a,3c), as well as the 
presence of plexiform giant neurofibroma in the 
subcutaneous fat of the right thigh and gluteal fat on 
the right, with the changes crossing the midline in the 
area of the external genitalia (Figure 3a).  
The presence of neurofibromas in the course 
of the iliac vessels on the right, with the larger one 
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measuring 75/49 mm (Figure 3a). Bladder with 
irregularly thickened walls and uneven internal outline 
contours (Figures 3a-3b, 3d). According to the image 
data, the finding engages the back wall diffusely in the 
area of the trigonum and the two urethral ostium, and 
in the trigonum area, the bladder wall is engaged in its 
entire volume (Figures 3a-3d). 
 
Figure 3: A), B) MRI images showing irregularly thickened walls and 
uneven internal contours of the bladder wall in the area of the 
trigonum and the two urethral ostia; C), D) Deformation of the 
anterior sacral wall with bilateral meningoceles at the Ec1 and Ec2 
levels and diffuse engagement of the posterior wall of the bladder in 
its entire volume 
 
The hospitalisation was planned in a 
neurosurgical unit for eventual surgical treatment. 
 
 
 
Discussion 
 
Data on patients with neurofibromatosis have 
existed since XIII and XVI centuries, and as early as 
1785- Mark Akensidi describes a case about a patient 
who was nicknamed "wart man" [1]. Subsequently, 
various descriptions and definitions of the disease 
arise, and it is currently thought that 
Neurofibromatosis type 1 (NF-1) or von 
Recklinghausen's disease is a disease of autosomal 
dominant transmission that is thought to have 
mutations in the NF1 gene on the long arm of 
chromosome 17 (17q11.2), resulting in a decrease in 
the production of neurofibromin protein, resulting in a 
lack of control of cell growth and division [2].  
Classically, the skin manifestations of NF1 are 
characterised by the presence of neurofibromas and 
café au lait spots variably distributed throughout the 
skin [7]. In some cases, however, neurofibromas are 
located along the nerves, in the subcutaneous tissue 
and follow the nerves affecting large areas and are 
defined as plexiform neurofibromas [8]. Patients with 
neurofibromatosis have a higher mortality rate which 
is mostly related to the possibility of malignant 
transformation of tumours [1].  
Patients are at risk for the transformation of 
NFs to malignant peripheral nerve sheath tumours 
(MPNSTs) or neurofibrosarcoma [4], [5], [6]. 
According to the literature data, particular attention 
should be paid to four markers (epidermal growth 
factor receptor, interferon-γ, interleukin-6, and tumour 
necrosis factor-α) to distinguish between patients with 
NF-1 and healthy subjects [9]. 
Even more significant (from a prognostic point 
of view) should be the determination of two additional 
markers as potential early risk predictors of 
developing MPNST (insulin-like growth factor binding 
protein 1 (IGFBP1)) and regulated upon activation, 
normal T-cell expressed and secreted (RANTES) in 
patients with type 1 neurofibromatosis and plexiform 
neurofibromas [9]. 
According to the majority of authors' 
collectives, patients with neurofibromatosis should be 
closely monitored and, where possible, excision of 
skin tumours or surgical treatment should be 
performed [1], [2], [3]. In many cases, however, 
surgical excision is complicated due to the 
involvement of the main nervous branches within the 
plexiform neurofibromas, and then the possibility of 
relapse after resection depends on the possibility of 
total or partial resection [4].  
We describe an interesting case of a patient 
with a giant, well-defined neurofibroma behind the 
bladder, as well as giant network-like sciatic plexiform 
neurofibroma engaging the genital area of the right, 
the gluteal region and the upper-medial part of the 
right thigh. Surgical excision of well-defined 
neurofibroma in the pelvic region should not be 
problematic and was planned in a neurosurgical ward 
at a later stage. Due to evidence of meningoceles in 
the sacral region, as well as an unfortunate 
localization of plerixiform neurofibroma in the 
pelvic/genital area, neurosurgeons currently restrain 
from surgical intervention. 
Alternative treatment for patients with type 1 
neurofibromatosis could be systemic therapy with 
Sirolimus (0.8 mg/m² body surface area by mouth for 
a 28-day course) [10]. Based on the available data, 
sirolimus treatment is appropriate for patients with 
progressive NF-1 type, inoperable, and it is not 
recommended for non-progressive forms of NF-1 [11]. 
Therapeutic alternatives should be considered. 
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